Home

Publication

Journal article

Report

Book

  1. Tran DT, Warkentin LM. Healthcare resource use and costs associated with extreme heat in Alberta, Canada. Discover Health Systems 2025;4(1):56. https://doi.org/10.1007/s44250-025-00238-2
  2. Razavilar N, Tran DT, Dukelow SP, Round J. Utilization of early supported discharge and outpatient rehabilitation services following inpatient stroke rehabilitation. Archives of Public Health 2024;82(1):80. https://doi.org/10.1186/s13690-024-01300-w
  3. Ritchie B, Martins KJB, Tran DT, Blain H, Richer L, Klarenbach SW. Economic impact of self-administered subcutaneous versus clinic-administered intravenous immunoglobulin g therapy in alberta, canada: A population-based cohort study. Allergy, Asthma & Clinical Immunology 2022;18(1):99. https://doi.org/10.1186/s13223-022-00735-6
  4. Tran DT, Yan C, Dukelow SP, Round J. Length of Stay and Home Discharge for Patients with Inpatient Stroke Rehabilitation. Can. J. Neurol. Sci. 2021:1-9. https://doi.org/10.1017/cjn.2021.238
  5. Tran DT, Palfrey D, Welsh R. The Healthcare Cost Burden in Adults with High Risk for Cardiovascular Disease. Pharmacoecon Open. 2021. https:/doi.org/10.1007/s41669-021-00257-8
  6. Kaul P, Tran DT, Sandhu RK, Solbiati M, Costantino G, Sheldon RS. Lack of benefit from hospitalization in patients with syncope: A propensity analysis. J Am Coll Emerg Physicians Open. 2020;1:716-722.
  7. Bagshaw SM, Tran DT, Opgenorth D, et al. Assessment of Costs of Avoidable Delays in Intensive Care Unit Discharge. JAMA Network Open. 2020;3:e2013913-e2013913.
  8. Tran DT, Palfrey D, Lo T, Welsh R. Outcome and Cost of Optimal Control of Dyslipidemia in Adults with High Risk for Cardiovascular Disease. Can J Cardiol. 2021;37:66-76.
  9. Tran DT, Sheldon RS, Kaul P, Sandhu RK. The Current and Future Hospitalization Cost Burden of Syncope in Canada. CJC Open. 2020;2:222-228.
  10. Bernier R, Tran DT, Sheldon R, Kaul P, Sandhu RK. A Population-based Study Evaluating Sex Differences in Patients Presenting to Emergency Departments with Syncope. JACC: Clinical Electrophysiology. 2020:1046.
  11. Tran DT, Akpinar I, Mayers I, Makhinova T, Jacobs P. Temporal Trends Of Pharmacologic Therapies For Patients With Chronic Obstructive Pulmonary Disease In Alberta, Canada. Int. J. Chron. Obstruct. Pulmon. Dis. 2019;14:2245-2256
  12. Tran DT, Akpinar I, Jacobs P. The Costs of Industry-Sponsored Drug Trials in Canada. Pharmacoecon Open. 2020;4:353-359.
  13. Tran DT, Thanh NX, Ohinmaa A, Mayers I, Jacobs P. Current and future direct healthcare cost burden of chronic obstructive pulmonary disease in Alberta, Canada. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine. 2019:1-9.
  14. Tran DT, Nguyen TX, Opgenorth D, Wang X, Zuege D, Zygun D, Stelfox H, Bagshaw SM. Association Between Strained ICU Capacity and Healthcare Costs: A Population-Based Cohort Study. J. Crit. Care. 2019;51:175-183.
  15. Tran DT, Barake W, Galbraith D, et al. Total and Cause-Specific Mortality After Percutaneous Coronary Intervention: Observations From the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease Registry. CJC Open. 2019;1:182-189.
  16. Bernier R, Ng J, Tran DT, et al. A Population-Based Study of Device Eligibility, Use, and Reasons for Nonimplantation in Patients at Heart Function Clinics. CJC Open. 2019;1:173-181.
  17. Akpinar I, Ohinmaa A, Thording L, et al. The Costs of Industry-Sponsored Medical Device Clinical Trials in Alberta. Pharmacoecon Open. 2019; 3:591-597.
  18. Akpinar I, Tran DT, Jacobs P. Publicly funded clinical research in Canada. Healthc. Manage. Forum. 2019;32:323-325.
  19. Tran DT, Akpinar I, Jacobs P. Pricing Clinical Research in the Canadian Industry. European Biophamaceutical Review. 2019; April 2019:62-63.
  20. Diepen SV, Tran DT, Ezekowitz JA, Schnell G, Wiley BM, Morrow BA, McAlister FA, Kaul P. Incremental Costs of High Intensive Care Utilization in Patients Hospitalized with Heart Failure. European heart journal. Acute cardiovascular care. 2019;0:2048872619845282
  21. Bisch SP, Wells T, Gramlich L, Faris P, Wang X, Tran DT, Thanh NX, Glaze S, Chu P, Ghatage P, Nation J, Capstick V, Steed H, Sabourin J, Nelson G. Enhanced Recovery After Surgery (ERAS) in gynecologic oncology: System-wide implementation and audit leads to improved value and patient outcomes. Gynecol. Oncol. 2018;151:117-123.
  22. Islam S, Kaul P, Tran DT, Mackie AS. Health Care Resource Utilization Among Children With Congenital Heart Disease: A Population-Based Study. Can J Cardiol. 2018;34:1289-1297.
  23. Tran DT, Welsh RC, Ohinmaa A, Thanh NX, Kaul P. Resource Use and Burden of Hospitalization, Outpatient, Physician, and Drug Costs in Short- and Long-term Care After Acute Myocardial Infarction. Can J Cardiol. 2018;34:1298-1306.
  24. Diepen VS, Tran DT, Ezekowitz JA, Zygun AD, Katz JN, Lopes RD, Newby LK, McAlister F, Kaul P. The high cost of critical care unit over-utilization for patients with NSTE ACS. Am Heart J 2018;202:84-88.
  25. Roston TM, Tran DT, Sanatani S, Sandhu R, Sheldon R, Kaul P. A Population-Based Study of Syncope in the Young. Can J Cardiol. 2018;34:195-201.
  26. Tran DT, Akpinar I, Fedorak R, Jonsson E, Mackey J, Richer L, Jacobs P. The Economic Contribution of Industry-Sponsored Pharmaceutical Clinical Trials. J. Pharm. Pharm. Sci. 2017;20:407-414.
  27. Tran DT, Ohinmaa A, Thanh NX, Welsh RC, Kaul P. The Health Care Cost Burden of Acute Myocardial Infarction in Alberta, Canada. PharmacoEconomics – Open. 2017. DOI: 10.1007/s41669-017-0061-0.
  28. Sandhu RK, Tran DT, Sheldon RS, Kaul P. A Population-based Cohort Study Evaluating Outcomes and Costs for Syncope Presentations to the Emergency Department. JACC: Clinical Electrophysiology. 2017. DOI: 10.1016/j.jacep.2017.09.003
  29. Tran DT, Welsh RC, Ohinmaa A, Thanh NX, Bagai A, Kaul P. Quality of Acute Myocardial Infarction Care in Canada: A 10-Year Review of 30-Day In-Hospital Mortality and 30-Day Hospital Readmission. Can J Cardiol. 2017;33:1319-1326.
  30. Bernier R, Raj SR, Tran DT, Reyes L, Sauve M, Sumner GL, Exner DV, Sandhu RK. Assessing physician knowledge regarding indications for a primary prevention implantable defibrillator and potential barriers for referral. J. Cardiovasc. Electrophysiol. 2017;28:1334-1341.
  31. Mackie AS, Tran DT, Marelli AJ, Kaul P. Cost of Congenital Heart Disease Hospitalizations in Canada: A Population-Based Study. Can J Cardiol. 2017;33:792-798.
  32. Tran DT, Welsh RC, Ohinmaa A, Thanh NX and Kaul P. Temporal Trends of Reperfusion Strategies and Hospital Mortality for Patients With STEMI in Percutaneous Coronary Intervention-Capable Hospitals. Can J Cardiol. 2017;33:485-492
  33. Akpinar I, Jacobs P, Tran DT. Forecasting Pharmaceutical Prices for Economic Evaluations When There Is No Market: A Review. PharmacoEconomics – Open. 2016;1(1):65-8.
  34. Tran DT, Ohinmaa A, Thanh NX, Howlett JG, Ezekowitz JA, McAlister FA, Kaul P. The current and future financial burden of hospital admissions for heart failure in Canada: a cost analysis. CMAJ Open. 2016;4:E365-E370.
  35. Thanh NX, Ezekowitz JA, Tran DT, Kaul P. Cost Effectiveness of Eplerenone for the Treatment of Systolic Heart Failure with Mild Symptoms in Alberta, Canada. Am. J. Cardiovasc. Drugs. 2016;16:365-376.
  36. Nguyen H, Wolfe M, Tran DT, McFarland D, Kamb M, Nguyen T, Hoang T, Del Rio C. 2011. Utilization of HIV Voluntary Counseling and Testing in Vietnam: An Evaluation of 5 Years of Routine Program Data for National Response. AIDS Education and Prevention, 23(3) Supplement, 30–48